| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 微芯生物是由资深留美归国博士团队于2001年3月创立的中国原创新药领域的先行者。公司秉承“原创、安全、优效、中国”的理念，专注对人类生命健康造成严重威胁的恶性肿瘤、代谢性疾病、自身免疫性疾病、中枢神经系统疾病及抗病毒五大领域的原创新药研发，致力于为患者提供可承受的、临床亟需的、具有革命性疗效的创新机制药物。微芯生物是科创板首家过会企业及第一家上市的生物医药企业（股票代码688321.SH）。 | ||||||||||||||||||||||||
| Main Business | 恶性肿瘤、代谢性疾病、自身免疫性疾病、中枢神经系统疾病及抗病毒五大领域的原创新药研发 | ||||||||||||||||||||||||
| Legal Representative | XIANPING LU | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 海鸥 | ||||||||||||||||||||||||
| Solicitors | 上海市通力律师事务所 | ||||||||||||||||||||||||
| Auditors | 毕马威华振会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0755-26952070 | ||||||||||||||||||||||||
| Fax No | 0755-26957291 | ||||||||||||||||||||||||
| Website | www.chipscreen.com | ||||||||||||||||||||||||
| ir@chipscreen.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 12/08/2019 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.218 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.856 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 6.231B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |